Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Refractory Solid Tumors: early-phase trial registry
3 of 8 indexed Refractory Solid Tumors trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,176 of 28,707 conditions by registered trial count.
8 US clinical trials · 3 currently recruiting · #2,176 of 28,707 conditions by registered trial count
Refractory Solid Tumors: 8 US clinical trials tracked, 3 recruiting.
Refractory Solid Tumors is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is OncoMed Pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition refractory-solid-tumors
OPEN 3 | RECR 38% | LATE 0 | EARLY 7 | RANK #2176 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute-graft-versus-host Disease (38% recruiting · 8 trials)
Refractory Solid Tumors lists 3 open slots (38% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Refractory Solid Tumors on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Refractory Solid Tumors is recruiting below its size-band peers.
3 of 8 indexed trials (37.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Refractory Solid Tumors trials is spread across many organizations.
OncoMed Pharmaceuticals accounts for 1 of 8 trials (12.5%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Refractory Solid Tumors trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 8 trials that report a genuine target (sentinel values excluded). 7 of those (87.5%) plan for fewer than 100 participants.
-
Refractory Solid Tumors research is mostly interventional.
7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
8 total, page 1 of 1
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
National Cancer Institute (NCI)
NCT03739827
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Theodore Laetsch
NCT06721689
A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
NCT06006273
A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
Idera Pharmaceuticals
NCT03052205
A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10
OncoMed Pharmaceuticals
NCT02482441
PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors
SCRI Development Innovations
NCT00759928
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)
Immatics US
NCT03247309
Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children
Stanford University
NCT02512926
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Refractory Solid Tumors records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Refractory Solid Tumors trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Refractory Solid Tumors page
8 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Refractory Solid Tumors trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- OncoMed Pharmaceuticals sponsors the most Refractory Solid Tumors trials on record, review their full trial history before evaluating a specific study. See OncoMed Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Refractory Solid Tumors condition card totals 8 registered trials; most-linked intervention OMP-131R10; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.